Form 4: BioLife Solutions Executive Todd Berard Reports Stock Transactions

Todd Berard, Chief Marketing Officer of BioLife Solutions, reports acquisition and disposal of company stock, including transactions made under a Rule 10b5-1 trading plan.

Summary

• On March 8, 2024, Todd Berard acquired 14,456 shares of common stock as part of his 2024 compensation under the BioLife Solutions 2023 Omnibus Performance Incentive Plan, which vests 25% on the first anniversary and then quarterly.
• He also acquired 17,523 shares of common stock on March 8, 2024, under the 2013 Performance Incentive Plan, vesting at 125% due to the company's total shareholder return from January 1, 2022, to December 31, 2023, compared to its peers.
• Berard sold 401 shares on March 11, 2024, at $17.42 per share and 7,107 shares on March 12, 2024, at $16.60 per share.
• These sales were executed under a Rule 10b5-1(c) trading plan adopted on February 24, 2022, to cover tax obligations related to vesting restricted stock.
• Following these transactions, Berard directly owns 140,159 shares of BioLife Solutions common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned strategy to cover tax obligations, but the sales could still raise concerns among some investors.

Positives

• The acquisition of shares reflects continued alignment of executive compensation with company performance.
• The vesting of shares under the 2013 Performance Incentive Plan indicates that the company met certain performance targets related to shareholder return.

Negatives

• The sale of shares, even under a pre-arranged plan, could be interpreted negatively by some investors.

Risks

• Executive stock sales, even for tax purposes, can sometimes create uncertainty in the market.
• Fluctuations in the stock price could impact the value of the remaining shares held by the reporting person.

Industry Context

Executive stock transactions are common in publicly traded companies and are often scrutinized by investors for insights into management's confidence in the company's future prospects. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without being accused of trading on non-public information.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• The vesting schedule of 25% on the first anniversary and then quarterly is a fairly standard vesting schedule for restricted stock grants.
• The use of total shareholder return as a performance metric is common in incentive plans to reward executives for creating value for shareholders.
• Compared to companies like Thermo Fisher Scientific or Danaher, BioLife Solutions is a smaller company, and executive compensation packages will likely reflect that difference in scale.

Stakeholder Impact

• Shareholders may react to the reported stock sales, although the existence of a pre-arranged trading plan mitigates potential concerns.
• The transactions have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates